Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Lewis Williams | M | 74 | 7 anni | |
| William Waddill | M | 67 | 8 anni | |
| Chirfi Guindo | M | 58 | 13 anni | |
| Bryan Giraudo | M | 49 | 6 anni | |
| Dalton Smart | M | 58 | 15 anni | |
| Carter J. King | M | 52 | 6 anni | |
| Richard DeLuca | M | 61 | 13 anni | |
| Ashok Bhandari | M | - | 7 anni | |
| Sanat Chattopadhyay | M | - | 15 anni | |
| Pamela Eisele | F | - | 15 anni | |
| Denise Williams | F | - | 15 anni | |
| Suneel Gupta | M | 66 | 5 anni | |
| Mohammad Masjedizadeh | M | - | 7 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Faheem Hasnain | M | 65 |
Abbott Biotherapeutics Corp.
 Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 2 anni |
| Timothy Shannon | M | 65 |
Aldea Pharmaceuticals, Inc.
 Aldea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aldea Pharmaceuticals, Inc. develops novel enzyme activators to enhance the removal of toxic aldehydes. It targets Aldehyde metabolism dysfunction which is associated with a variety of diseases from acute alcohol toxicity to orphan indications such as Fanconi anemia. The company was founded by Daria Mochly-Rosen, Che-Hong Chen and Wenjin Yang in 2011 and is headquartered in Redwood City, CA. | 3 anni |
| Richard Clark | M | 77 | 6 anni | |
| Fred Hassan | M | 78 | 6 anni | |
| Carlos Eduardo Represas de Almeida | M | 78 | - | |
| Samuel Saks | M | 69 | - | |
| Julie Gerberding | M | 69 | - | |
| Thomas O'Neil | M | 59 | 3 anni | |
| Bradford Goodwin | M | 69 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 2 anni |
| Michael Nally | M | 48 | 10 anni | |
| Thomas Robert Cech | M | 76 | - | |
| Thomas Shenk | M | 77 | 11 anni | |
| Harry R. Jacobson | M | 76 | 3 anni | |
| Jean-Marie Canan | M | 68 | 5 anni | |
| Herbert Cross | M | 52 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | - |
| Steven Goldstone | M | 78 | 6 anni | |
| Francis Sarena | M | 53 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 2 anni |
| Caroline Dorsa | F | 64 | 22 anni | |
| Julie Grant | F | 41 | 2 anni | |
| Sarah Noonberg | M | 56 | 6 anni | |
| William N. Kelley | M | 84 | - | |
| Jeffrey Chodakewitz | M | 68 | 4 anni | |
| D. Gilliland | M | 69 | 4 anni | |
| Yan Li | F | 50 | 4 anni | |
| Graham Lumsden | M | 64 | 26 anni | |
| Gwen R. Carscadden | F | 62 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 2 anni |
| Rasappa Arumugham | M | 73 | 2 anni | |
| Mark Shearman | M | 62 | 3 anni | |
| Stephen Farrand | M | - | 6 anni | |
| Terrie Curran | F | 55 | 4 anni | |
| Timothy Murphy | M | 56 | 4 anni | |
| Sachin Jain | M | 43 | 2 anni | |
| Doron Ben-Ami | M | 72 | 5 anni | |
| Maarten van der Linden | M | 55 | 4 anni | |
| Lucio Tozzi | M | 60 | 4 anni | |
| Jens Renstrup | M | 59 | 8 anni | |
| Arnaub Chatterjee | M | - | 5 anni | |
| Jim Robinson | M | - | 5 anni | |
| Gerard Cunningham | M | - | 1 anni | |
| Carlos Lugo | M | - | 2 anni | |
| Mark Bach | M | 67 | 17 anni | |
| Yanni Souroutzidis | M | - | 2 anni | |
| Rafael Torgovicky | M | - | 2 anni | |
| Francesco Maria Lavino | M | 51 | 2 anni | |
| Sheldon Koenig | M | 58 | 6 anni | |
| Pernilla Sandwall | F | 61 | 8 anni | |
| Yao Lee | M | 54 | 3 anni | |
| Ernesto Aycardi | M | 61 | 11 anni | |
| Alexis Ji | M | - | 5 anni | |
| Hugo Wahnish | M | - | 18 anni | |
| Geralyn S. Ritter | F | - | 8 anni | |
| Lawrence D. Senour | M | 59 | - | |
| Vijay Tammara | M | 64 | 6 anni | |
| Andrew Guggenhime | M | 55 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 2 anni |
| Bridgette Heller | F | 62 | 5 anni | |
| Dennis Erb | M | - | - | |
| Richard S. Bowles | M | 72 | - | |
| Evgeny Zaytsev | M | 56 |
Aldea Pharmaceuticals, Inc.
Aldea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aldea Pharmaceuticals, Inc. develops novel enzyme activators to enhance the removal of toxic aldehydes. It targets Aldehyde metabolism dysfunction which is associated with a variety of diseases from acute alcohol toxicity to orphan indications such as Fanconi anemia. The company was founded by Daria Mochly-Rosen, Che-Hong Chen and Wenjin Yang in 2011 and is headquartered in Redwood City, CA. | - |
| Jaisim Shah | M | 63 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 1 anni |
| Margaret McGlynn | F | 64 | 11 anni | |
| Gary Lyons | M | 73 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 2 anni |
| David Parkinson | M | 73 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 2 anni |
| Samuel O. Thier | M | 86 | 16 anni | |
| Pam Cheng | F | 53 | 5 anni | |
| Ted Llana | M | 60 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | - |
| Stefan Oschmann | M | 66 | 20 anni | |
| James Christopher Scalet | M | 65 | 9 anni | |
| Raul E. Kohan | M | 71 | 1 anni | |
| Mark McCamish | M | 72 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 1 anni |
| Anthony Rimac | M | 60 |
Aldea Pharmaceuticals, Inc.
Aldea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aldea Pharmaceuticals, Inc. develops novel enzyme activators to enhance the removal of toxic aldehydes. It targets Aldehyde metabolism dysfunction which is associated with a variety of diseases from acute alcohol toxicity to orphan indications such as Fanconi anemia. The company was founded by Daria Mochly-Rosen, Che-Hong Chen and Wenjin Yang in 2011 and is headquartered in Redwood City, CA. | 1 anni |
| Franklin Clyburn | M | 59 | 13 anni | |
| Peter Honig | M | 67 | 7 anni | |
| Glenn Williams | M | - | 10 anni | |
| Roger Pomerantz | M | 67 | 3 anni | |
| Bruno Strigini | M | 63 | 5 anni | |
| Eric Schadt | M | 59 | 8 anni | |
| Aaron Dent | M | - | 6 anni | |
| David A. Esposito | M | 55 | 13 anni | |
| Piotr Bobrowicz | M | - | - | |
| David Monteith | M | 60 | 5 anni | |
| Daniel Bouthillier | M | - | 16 anni | |
| Christopher Garland | M | - | - | |
| Cuong Viet Do | M | 58 | 3 anni | |
| Ami Knoefler | F | - |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 1 anni |
| Graeme Bell | M | 57 | 2 anni | |
| Michael Holston | M | 61 | 6 anni | |
| Milenko Cicmil | M | - | - |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 100 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Richard S. Shames
- Contatti personali
